Profit hopes shore up Zeneca defence
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MAGNUS GRIMOND
The drugs and chemicals group Zeneca has in effect shored up its bid defences by announcing a pounds 60m charge to improve efficiency and indicating that profits for last year will be at the upper end of expectations.
Forecasts, previously pitched at between pounds 820m and pounds 885m ahead of exceptional charges, were being edged up to a consensus figure of about pounds 870m for the year ending last December following yesterday's announcement.
Bid rumours, centring on Swiss drugs giant Roche Holding of Switzerland, have swirled around Zeneca for months. The profits estimate, coming alongside moves by the company to further boost efficiency in the pharmaceuticals operation, will push up any price a bidder might have to pay, while limiting the scope for a new owner to further cut costs.
The shares dipped 14p to pounds 12.85 yesterday, although dealers said this had less to do with punctured bid hopes than the aftermath of an issue of warrants in the shares by brokers Barclays de Zoete Wedd on Monday. Zeneca traditionally updates the market on current trading in January, while the pounds 60m provision comes half-way through a two-year programme to "re-engineer" the pharmaceuticals business to cut costs and working capital. None the less, yesterday's news will have done it no harm in fending off a bid, should it emerge.
Zeneca's healthy profits for last year have come on the back of strong fourth-quarter sales in pharmaceuticals, which have pushed growth in the whole of 1995 ahead of the trend for the first nine months.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments